William Blair analyst Andy Hsieh reiterated a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today. The company’s shares opened today at $7.10. Effectively assess a stock's ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) yesterday and set a price target of $65.00. The company’s shares closed yesterday ...

Corbus Pharmaceuticals (CRBP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...

Shares of CRBP stock opened at $6.79 on Wednesday. The stock’s 50-day simple moving average is $9.44 and its 200-day simple moving average is $18.99. The firm has a market capitalization of $82. ...

Shares of CRBP stock opened at $6.79 on Friday. The stock’s 50 day simple moving average is $9.44 and its 200 day simple moving average is $18.99. Corbus Pharmaceuticals has a twelve month low ...

NORWOOD, Mass. (AP) — NORWOOD, Mass. (AP) — Corbus Pharmaceuticals Holdings Inc. (CRBP) on Tuesday reported a loss of $9.5 million in its fourth quarter. The Norwood, Massachusetts-based ...

Fintel reports that on February 28, 2025, William Blair initiated coverage of Corbus Pharmaceuticals Holdings (NasdaqCM:CRBP) with a Outperform recommendation. Analyst Price Forecast Suggests 690. ...

The ongoing crisis in Sudan has exposed more than 12 million people to widespread sexual violence, according to the United Nations Children's Fund (UNICEF). As the war nears its two-year mark ...